LSE : 0J9P.L

Incyte Corporation

$117.97 USD

$1.73 (1.49%)

Volume
210
Average Volume
2.83K
Market Capitalization
$23.57B
P/E Ratio
16.12
Dividend Yield
0.00%
Price Target
Year High
$119.01
Year Low
$50.81
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$3.68
Company Overview

LSE

William J. Meury

Medical - Pharmaceuticals

Healthcare

0J9P.L

2844

US

USD

https://www.incyte.com

302 498 6700

45337C102

N/A

Liquidity Metrics

0.01

3.68

3.60

2.32

0.00

Sales & Valuation

$5.14B

4.39

4.22

16.20

7.28

Profitability

$6.41

$1.29B

26.71%

33.09%

29.31%

19.51%

P/E Metrics

16.12

0.01

0.01

Analyst Price Target & Rating

Buy

4/5

42 Analysts

%

Financial Health Scores

10.45

6/9

$4.35B

$7.34B

$1.72B

$1.75B

Key Metrics (TTM)

No key metrics data available.

Company Executives
Name Title
Alexis Smith Vice President & Head of Investor Relations
Richard A. Hoffman Executive VP, General Counsel & Secretary
Lee J. Heeson Executive VP & Head of Incyte International
Mohamed Khairie Issa Executive Vice President & Head of U.S. Commercial
Suketu Upadhyay Executive Vice President & Chief Financial Officer
William Meury CEO & Director
Soni K. Basi Executive Vice President & Chief Human Resources Officer
Xiaozhao Wang Associate VP & Head of Medicinal Chemistry
Pamela Murphy Vice President of Investor Relations & Corporate Communications
Thomas Tray Principal Financial Officer, Vice President of Finance & Chief Accounting Officer
Steven H. Stein Executive VP, Head of Late-stage Development & Chief Medical Officer
Pablo J. Cagnoni President and Global Head of Research & Development
Michael James Morrissey Executive Vice President & Head of Global Technical Operations
James H. Lee Group VP, Head of Inflammation & AutoImmunity Group
Poll Results

No votes yet today — be the first to share your view!

About Incyte Corporation (LSE:0J9P.L) Stock

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for ... the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Frequently Asked Questions

What is the current Incyte Corporation (0J9P.L) stock price?

Incyte Corporation(LSE:0J9P.L) stock price is $117.97 in the last trading session. During the trading session, 0J9P.L stock reached the peak price of $119.01 while $50.81 was the lowest point it dropped to. The percentage change in 0J9P.L stock occurred in the recent session was 1.49% while the dollar amount for the price change in 0J9P.L stock was $1.73.

0J9P.L's industry and sector of operation?

The LSE listed 0J9P.L is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.

Who are the executives of 0J9P.L?

Alexis Smith | Vice President & Head of Investor Relations
Richard A. Hoffman | Executive VP, General Counsel & Secretary
Lee J. Heeson | Executive VP & Head of Incyte International
Mohamed Khairie Issa | Executive Vice President & Head of U.S. Commercial
Suketu Upadhyay | Executive Vice President & Chief Financial Officer

How many employees does 0J9P.L have?

Number of 0J9P.L employees currently stands at 2844. 0J9P.L operates from 1801 Augustine Cut-Off, Wilmington, DE 19803, US.

Link for 0J9P.L official website?

Official Website of 0J9P.L is: https://www.incyte.com

How do I contact 0J9P.L?

0J9P.L could be contacted at phone #302 498 6700 and can also be accessed through its website. 0J9P.L operates from 1801 Augustine Cut-Off, Wilmington, DE 19803, US.

How many shares of 0J9P.L are traded daily?

The average number of 0J9P.L shares traded daily for last 3 months was 2.83K.

What is the market cap of 0J9P.L currently?

The market value of 0J9P.L currently stands at $23.57B with its latest stock price at $117.97